Skip to main content

Monopar Therapeutics

MNPR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001645469

In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 3 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.

13F holders, Q4 2024

Institutional positions in Monopar Therapeutics as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
18
+12 vs. Q3 2024
Shares held
2.58M
+2.56M (+16,314.9%) vs. Q3 2024
Total value
$57.1M
+$57.0M (+53,860.7%) vs. Q3 2024
New holders
12
3 more added
Sold out
0
1 more reduced

Compare with Q3 2024: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting MNPR on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2024: 18 institutions
Q1 2021: 13 institutionsQ2 2021: 10 institutionsQ3 2021: 9 institutionsQ4 2021: 13 institutionsQ1 2022: 13 institutionsQ2 2022: 13 institutionsQ3 2022: 10 institutionsQ4 2022: 10 institutionsQ1 2023: 11 institutionsQ2 2023: 8 institutionsQ3 2023: 14 institutionsQ4 2023: 14 institutionsQ1 2024: 16 institutionsQ2 2024: 12 institutionsQ3 2024: 6 institutionsQ4 2024: 18 institutionsQ1 2025: 35 institutionsQ2 2025: 43 institutionsQ3 2025: 56 institutionsQ4 2025: 74 institutionsQ1 2026: 82 institutionsQ2 2026: 95 institutions
Value heldQ4 2024: $57.1M
Q1 2021: $1.21MQ2 2021: $1.10MQ3 2021: $964.4KQ4 2021: $657.2KQ1 2022: $519.8KQ2 2022: $470.6KQ3 2022: $314.0KQ4 2022: $471.0KQ1 2023: $322.9KQ2 2023: $164.5KQ3 2023: $182.2KQ4 2023: $91.7KQ1 2024: $268.1KQ2 2024: $310.1KQ3 2024: $105.9KQ4 2024: $57.1MQ1 2025: $109.4MQ2 2025: $113.3MQ3 2025: $354.3MQ4 2025: $360.8MQ1 2026: $341.5MQ2 2026: $576.1M
Institutions holding MNPR and their total value by quarter
QuarterHoldersValue
Q2 202695$576.1M
Q1 202682$341.5M
Q4 202574$360.8M
Q3 202556$354.3M
Q2 202543$113.3M
Q1 202535$109.4M
Q4 202418$57.1M
Q3 20246$105.9K
Q2 202412$310.1K
Q1 202416$268.1K
Q4 202314$91.7K
Q3 202314$182.2K
Q2 20238$164.5K
Q1 202311$322.9K
Q4 202210$471.0K
Q3 202210$314.0K
Q2 202213$470.6K
Q1 202213$519.8K
Q4 202113$657.2K
Q3 20219$964.4K
Q2 202110$1.10M
Q1 202113$1.21M

Institutions, Q4 2024

Shares, value and share of portfolio for each institution holding Monopar Therapeutics; share changes are against Q3 2024.

Institutions holding MNPR in Q4 2024
InstitutionSharesValue% of portfolioChange in sharesAction
Janus Henderson Group PLC1,046,899$23.4M0.01%+1,046,899New
Adage Capital Partners GP, L.L.C.599,195$13.2M0.02%+599,195New
Ra Capital Management, L.P.511,207$11.2M0.15%+511,207New
Point72 Asset Management, L.P.167,892$3.69M0.01%+167,892New
ADAR1 Capital Management, LLC130,037$2.86M0.59%+130,037New
Vanguard Group Inc56,509$1.24M0.00%+56,509New
Geode Capital Management, LLC38,596$849.1K0.00%+24,530+174.4%Added
BlackRock, Inc.8,101$178.2K0.00%+8,101New
UBS Group AG6,423$141.3K0.00%+5,911+1,154.5%Added
Ikarian Capital, LLC5,908$130.0K0.04%+5,908New
Morgan Stanley3,801$83.6K0.00%+3,801New
JPMorgan Chase & Co2,037$44.8K0.00%+2,037New
Tower Research Capital LLC (TRC)696$15.3K0.00%+696New
GWM Advisors LLC600$13.2K0.00%00.0%Unchanged
Wells Fargo & Company250$5.50K0.00%−250−50.0%Reduced
SBI Securities Co., Ltd.100$2.20K0.00%+100New
Bank of America Corp28$6160.00%+15+115.4%Added
Federation des caisses Desjardins du Quebec16$3520.00%00.0%Unchanged